Tous Actualités
Suivre
Abonner Intercell AG

Intercell AG

euro adhoc: Intercell AG
other
Staphylococcus aureus vaccine development on track - safe and immunogenic in Phase I clinical trials

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
Research & Development
18.05.2007
Vienna (Austria), May 18, 2007 - Intercell AG (VSE, "ICLL") has been 
informed by its strategic partner Merck & Co., Inc.  on the results 
of a Phase I study involving in total over 120 adult healthy 
volunteers comparing safety and immunogenicity of different doses of 
the Staphylococcus aureus vaccine.
The Staphylococcus aureus vaccine is based on a conserved protein 
antigen discovered by Intercell´s Antigen Identification Program 
(AIP®) and was licensed to Merck & Co., Inc.  on an exclusive world 
wide basis in 2003.
The data show that the vaccine is safe and generally well tolerated. 
Immune responses were observed within several weeks following 
vaccination and these immune responses persisted throughout the 
course of the study.
"We are very pleased that the vaccine candidate, for which the 
antigen was identified by our proprietary AIP®  technology, delivered
promising clinical data, and look forward to its further clinical 
development ", states Gerd Zettlmeissl, CEO of Intercell. "These data
underline the high potential of our AIP® technology for the 
identification of other bacterial vaccine product candidates in-house
or in collaboration with leading vaccine companies".
About Staphylococcus aureus and nosocomial infections
Hospital-acquired infections are one of the major causes of death and
serious illness worldwide, resulting in an annual burden of more than
USD 20 billion in the developed world. In the United States alone, 
about two million patients become infected annually while receiving 
health care in hospitals. The incidence of nosocomial infections is 
steadily increasing due to medical interventions and most notably due
to the emergence of antibiotic resistant bacteria circulating in 
hospitals. Staphylococcus aureus is the most frequent cause of 
hospital acquired infections. In addition to bloodstream infections 
with a mortality rate of up to 35%, infections of bone, heart and 
other inner organs are leading to serious health complications, death
and economic burden. Today, approximately 50% of Staphylococcus 
aureus strains isolated in hospitals worldwide are resistant to 
multiple antibiotics, rendering staphylococcal disease management 
increasingly difficult and challenging.
end of announcement                               euro adhoc 18.05.2007 06:45:00

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market

Plus de actualités: Intercell AG
Plus de actualités: Intercell AG